Physician profile
Patrick S Carroll
NPI 1700947181
$1,235.59
in general payments reported to CMS, 2019-2025
24 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.33 · 2022: $137 · 2023: $651 · 2024: $188 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $177.60 | 2022-2023 | Belbuca |
| Providence Medical Technology, INC. | $157.45 | 2025 | |
| Medtronic, INC. | $129.53 | 2022-2023 | Intellis Adaptivestim |
| Lundbeck LLC | $89.45 | 2023 | Vyepti |
| Forte Bio-Pharma LLC | $75.04 | 2022-2023 | Prolate, Nalocet |
| Abbvie INC. | $65.39 | 2023 | |
| Nevro Corp. | $59.61 | 2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.59 | 2022-2023 | Relistor |
| Kowa Pharmaceuticals America, INC. | $55.24 | 2022-2024 | Seglentis, Livalo |
| Bioventus LLC | $44.66 | 2021-2025 | Xcell |
| Irhythm Technologies, INC. | $40.02 | 2024 | Zio Monitor, Zio Xt Patch |
| Vertex Pharmaceuticals Incorporated | $33.67 | 2025 | |
| Pfizer INC. | $29.38 | 2023 | |
| United Therapeutics Corporation | $29.04 | 2024 | Tyvaso |
| Medicomp INC | $26.74 | 2024 | Telepatch Cardiac Monitor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $23.14 | 2025 | Hymovis, Triluron |
| Scilex Pharmaceuticals INC. | $21.73 | 2023 | Ztlido |
| Azurity Pharmaceuticals, INC. | $20.77 | 2023 | Horizant |
| Biohaven Pharmaceutical Holding Company LTD. | $18.79 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $18.66 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $18.07 | 2024 | Exparel, Iovera, Zilretta |
| Daiichi Sankyo INC. | $17.42 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $17.40 | 2024 | |
| Ossur Americas, INC. | $7.20 | 2024 | Miami J |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.